| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -10.9 | -137.9 |
| Net income | -9.8 | -137.7 |
| EPS (diluted, $ a share) | $-0.31 | $-1.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CMPS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Compass Pathways plc: key numbers
- Share price
- $8.27Close, Nov 16
- Market cap
- $1.17B
- Shares outstanding
- 141.71MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Compass Pathways plc
All →Compass Pathways Financial Results
Compass Pathways reported Q3 2026 financial results, highlighting a strong cash position of $444 million and the imminent completion of its rolling NDA submission for COMP360 in treatment-resistant depression (TRD). The company expects a potential commercial launch in the first half of 2027, supported by positive Phase 3 data and a National Priority Voucher that could accelerate FDA review.
- Term
- Q3 2026
“Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm.”
Kabir Nath, Chief Executive Officer of Compass Pathways